This study enrolls people with TRK fusion cancer. The purpose of this study is to learn more about the effectiveness of the drug VITRAKVI (generic name: larotrectinib) for TRK fusion cancer that has spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. Read More
Patients with TRK fusion cancer (locally advanced or metastatic solid tumor harboring an NTRK gene fusion).
Your physician has decided to treat you with larotrectinib.
This study enrolls adults with esophageal cancer. The purpose of this study is to compare the effects of different combinations of medications to treat this cancer. Atezolizumab and tiragolumab are experimental drugs, which means the U.S. Food and Drug Administration (FDA) has not approved them, alone or in combination, for the treatment of esophageal cancer. Read More
Adults ages 18+.
Diagnosed with esophageal cancer (squamous cell carcinoma of the esophagus) in stage II-IIVA.
The cancer is unresectable, which means you are unable to unwilling to have surgery.
You have received chemoradiotherapy and your disease did not worsen.
This study enrolls adults who have been diagnosed with borderline personality disorder. This study is being done to see if the study drug called, BI 1358894, may help people with BPD in the future. Read More
Adults ages 18-65 years.
Diagnosed with Borderline Personality Disorder.
This study enrolls people with Multiple Sclerosis who have already enrolled in the New York State Multiple Sclerosis Consortium (NYSMSC). The purpose of this study is to learn more about the experiences of people with MS who are having a natalizumab infusion. Read More
Adults ages 18+.
Have multiple sclerosis.
Are enrolled in the New York State Multiple Sclerosis Consortium (NYSMSC),
Have taken natalizumab for the treatment of MS for at least six months.
This study enrolls adults who come to the Buffalo General Medical Center emergency department who may have COVID-19. The purpose of this research study is to help us find a way to learn which patients are at risk of developing a severe COVID-19 infection versus a less severe COVID-19 infection. We will do this by looking at immune cells in blood. Read More
Adults ages 18+.
Come to the emergency department at Buffalo General Medical Center with suspicion of COVID-19.
This study is not open for open enrollment- you may be invited to participate if you meet other eligibility criteria and are at the BGMC emergency department.
This study enrolls adults who have had heart failure or heart attack or who are generally healthy. The purpose of this study is to learn more about how these types of cardiovascular issues happen at a biological level. We will do that by looking at the immune cells in the blood. Read More
Adults ages 18+
Generally healthy OR are presenting to the hospital with heart failure or acute myocardial infarction (heart attack).
This study enrolls older adults ages 60+. We are looking for adults who are not active who have Type 2 Diabetes and also physically active older adults. The purpose of the study is to learn if a 2-month home-based exercise program will help improve oxygen levels and fitness. Read More
Adults ages 60+.
Able to walk and follow simple exercise instruction.
Two groups will be enrolled:
1. People with Type 2 Diabetes with a low level of physical activity right now.
2. Physically active people (do cycling, strength training or walking faster than usual for 60+ minutes per week) with or without type 2 diabetes.